Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 111, Issue 51, Pages E5564-E5573
Publisher
Proceedings of the National Academy of Sciences
Online
2014-12-16
DOI
10.1073/pnas.1419260111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy
- (2014) Marieke L Kuijjer et al. BMC Medical Genomics
- BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
- (2014) Bérengère Gobin et al. INTERNATIONAL JOURNAL OF CANCER
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- (2014) Simon A. Forbes et al. NUCLEIC ACIDS RESEARCH
- Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
- (2014) Xiang Chen et al. Cell Reports
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chromoplexy: A New Category of Complex Rearrangements in the Cancer Genome
- (2013) Michael M. Shen CANCER CELL
- NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate
- (2013) Bérengère Gobin et al. CANCER LETTERS
- Punctuated Evolution of Prostate Cancer Genomes
- (2013) Sylvan C. Baca et al. CELL
- The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models
- (2013) Y. Pignochino et al. CLINICAL CANCER RESEARCH
- Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in Melanoma
- (2013) L. N. Kwong et al. CLINICAL CANCER RESEARCH
- New Insights Into the Role of Sequestosome 1/p62 Mutant Proteins in the Pathogenesis of Paget's Disease of Bone
- (2013) Sarah L. Rea et al. ENDOCRINE REVIEWS
- Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
- (2013) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
- (2013) John J Bissler et al. LANCET
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
- (2013) Kristian Cibulskis et al. NATURE BIOTECHNOLOGY
- Genome-wide association study identifies two susceptibility loci for osteosarcoma
- (2013) Sharon A Savage et al. NATURE GENETICS
- MicroRNA-221 Induces Cell Survival and Cisplatin Resistance through PI3K/Akt Pathway in Human Osteosarcoma
- (2013) Guangyi Zhao et al. PLoS One
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K–Akt signaling
- (2012) Kelai Wang et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations
- (2012) Tobias Rausch et al. CELL
- Mutational Processes Molding the Genomes of 21 Breast Cancers
- (2012) Serena Nik-Zainal et al. CELL
- Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability
- (2012) Y. Drier et al. GENOME RESEARCH
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway
- (2012) Masanobu Tsubaki et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Genetic determinants of Paget's disease of bone
- (2011) Stuart H. Ralston et al. Annals of the New York Academy of Sciences
- High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
- (2011) Edwin Choy et al. CANCER
- Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells
- (2011) Euphemia Leung et al. CANCER BIOLOGY & THERAPY
- Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development
- (2011) Philip J. Stephens et al. CELL
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- PathSeq: software to identify or discover microbes by deep sequencing of human tissue
- (2011) Aleksandar D Kostic et al. NATURE BIOTECHNOLOGY
- High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
- (2011) Lydia W.T. Cheung et al. Cancer Discovery
- GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
- (2011) Craig H Mermel et al. GENOME BIOLOGY
- Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil
- (2010) Ana Luiza Seidinger et al. CANCER
- Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process
- (2010) G. Moriceau et al. CANCER RESEARCH
- A method and server for predicting damaging missense mutations
- (2010) Ivan A Adzhubei et al. NATURE METHODS
- Osteosarcoma incidence and survival rates from 1973 to 2004
- (2009) Lisa Mirabello et al. CANCER
- mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis
- (2009) Quan Zhou et al. MEDICAL ONCOLOGY
- Copy number gains inEGFRand copy number losses inPTENare common events in osteosarcoma tumors
- (2008) Serena S. Freeman et al. CANCER
- Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease
- (2008) C. R. Walkley et al. GENES & DEVELOPMENT
- Highly parallel identification of essential genes in cancer cells
- (2008) B. Luo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started